The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis
Abstract
Objective: Control of rheumatoid arthritis (RA) may reduce the risk of cardiovascular events. We sought to systematically assess the association between anti–tumor necrosis factor α (anti‐TNFα) therapy in RA and cardiovascular event rates. Methods: Observational cohorts and randomized controlled trials (RCTs) reporting on cardiovascular events (all events, myocardial infarction [MI], congestive heart failure, and cerebrovascular accident [CVA]) in RA patients treated with anti‐TNFα therapy compared to traditional disease‐modifying antirheumatic drugs were identified from a search of PubMed (1950 to November 2009), EMBase (1980 to November 2009), and conference abstracts. Relative risks (RRs) or hazard ratios and 95% confidence intervals (95% CIs) were extracted. If the incidence was reported, additional data were extracted to calculate an incidence density ratio and its variance. Results: The systematic review and meta‐analysis include 16 and 11 publications, respectively. In cohort studies, anti‐TNFα therapy was associated with a reduced risk for all cardiovascular events (pooled adjusted RR 0.46; 95% CI 0.28, 0.77), MI (pooled adjusted RR 0.81; 95% CI 0.68, 0.96), and CVA (pooled adjusted RR 0.69; 95% CI 0.53, 0.89). Meta‐analysis of RCTs also produced a point estimate indicating lower risk of cardiovascular events, but this was not statistically significant (pooled RR 0.85; 95% CI 0.28, 2.59). Conclusion: Anti‐TNFα therapy is associated with a reduced risk of all cardiovascular events, MI, and CVA in observational cohorts. There was heterogeneity among cohort studies and possible publication bias. The point estimate of the effect from RCTs is underpowered with wide 95% CIs, and cardiovascular events were secondary outcomes, but RCTs also demonstrated a trend toward decreased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Aviña‐Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. (2008) · Arthritis Care & Research · doi:10.1002/art.24092 · Cited by 1,462
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.113696 · Cited by 1,325 · cited 1×
“Recent recommendations from the European League Against Rheumatism reinforce the importance of early aggressive treatment of inflammatory arthritis with anti-TNF and methotrexate treatment for the specific purpose of lowering cardiovascular risk in two ways (30).”
BackgroundSt. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22809 · Cited by 562
Jacobsson, L., Turesson, C., Gülfe, A., Kapetanovic, M. C., Petersson, I. F., Saxne, T., & Geborek, P. (2005) · PubMed · Cited by 533
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Naranjo, A., Sokka, T., Descalzo, M. A., Calvo-Alén, J., Hørslev-Petersen, K., Luukkainen, R. K., Combe, B., Burmester, G. R., Devlin, J., Ferraccioli, G., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2383 · Cited by 467
Meune, C., Touze, E., Trinquart, L., & Allanore, Y. (2009) · Rheumatology · doi:10.1093/rheumatology/kep252 · Cited by 431
Wolfe, F., & Michaud, K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.039 · Cited by 372
Westlake, S. L., Colebatch, A. N., Baird, J., Kiely, P., Quinn, M., Choy, E., Ostor, A. J. K., & Edwards, C. J. (2010) · Rheumatology · doi:10.1093/rheumatology/kep366 · Cited by 357
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
Carmona, L., Descalzo, M. Á., Perez-Pampin, E., Ruiz-Montesinos, D., Erra, A., Cobo, T., & Gómez-Reino, J. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067660 · Cited by 231
Gonzalez‐Juanatey, C., Testa, A., Garcia‐Castelo, A., Garcia‐Porrua, C., Llorca, J., & Gonzalez‐Gay, M. A. (2004) · Arthritis Care & Research · doi:10.1002/art.20407 · Cited by 227
Listing, J., Strangfeld, A., Kekow, J., Schneider, M., Kapelle, A., Wassenberg, S., & Zink, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23281 · Cited by 195
Setoguchi, S., Schneeweiß, S., Avorn, J., Katz, J. N., Weinblatt, M. E., Levin, R., & Solomon, D. H. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.02.025 · Cited by 132
Lévy, L., Fautrel, B., Barnetche, T., & Schaeverbeke, T. (2008) · PubMed · Cited by 113
van Eijk, I. C., de Vries, M. K., Levels, J. H. M., Peters, M. J. L., Huizer, E. E., Dijkmans, B. A. C., van der Horst-Bruinsma, I. E., Hazenberg, B. P. C., van de Stadt, R. J., Wolbink, G., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24492 · Cited by 112
Mortality Reduction with Influenza Vaccine in Patients with Pneumonia Outside “Flu” Season
Eurich, D. T., Marrie, T. J., Johnstone, J., & Majumdar, S. R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-282oc · Cited by 108
González‐Juanatey, C., Llorca, J., Vázquez-Rodríguez, T. R., Varela, N. D., García-Quiroga, H., & González-Gay, M. Á. (2008) · Arthritis Care & Research · doi:10.1002/art.24308 · Cited by 102
Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs
Avouac, J., & Allanore, Y. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1121 · Cited by 93
Sidiropoulos, P. I., Siakka, P., Pagonidis, K., Raptopoulou, A., Kritikos, H. D., Tsetis, D. K., & Boumpas, D. T. (2008) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740802363768 · Cited by 92
Garbe, E., & Suissa, S. (2003) · Human Reproduction · doi:10.1093/humrep/deh022 · Cited by 79
Cole, J., Busti, A. J., & Kazi, S. (2006) · Rheumatology International · doi:10.1007/s00296-006-0215-3 · Cited by 58
Cuchacovich, R., & Espinoza, L. R. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1208-x · Cited by 29
Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Boyer, J., Cantagrel, A. G., & Constantin, A. (2008) · Current Vascular Pharmacology · doi:10.2174/157016108784911975 · Cited by 17
Cited by
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109927 · Cited by 1,816
Agca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., Kvien, T. K., Dougados, M., Radner, H., Atzeni, F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209775 · Cited by 1,380
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Metadata
- Authors
- Barnabe, C., Martin, B., & Ghali, W. A.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2011-03-30
- Volume
- 63
- Issue
- 4
- Pages
- 522-529
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W2062105256
- Cited by
- 368
- References
- 32
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.